An AI-focused research, venture-building, and investment group focused on developing and commercialising foundational artificial intelligence technologies. The group builds, accelerates, and scales companies operating at the intersection of cognitive architectures, machine creativity, agent-based systems, and applied machine learning. Its portfolio spans generative content engines, audio fingerprinting, AI-driven productivity systems, research automation tools, fan-engagement applications, audio remixing, AI video technologies, and other applied AI solutions. The organisation combines deep scientific research, a computational laboratory model, and structured venture creation to develop defensible intellectual property and scalable commercial solutions. It is currently raising capital to expand its regional presence in the Middle East and North Africa, launch applied AI laboratories, and build long-term research capabilities aligned with regional innovation and technology-development priorities.

A leading global asset management platform with a strong presence across Asia, managing institutional and wholesale capital across equities, fixed income, multi-asset solutions, quantitative strategies, and private markets. With investment teams based across Asia and key global hubs, the platform manages substantial assets and delivers active, research-driven investment strategies tailored for pension funds, insurers, sovereign institutions, and global allocators. Capabilities span Asian equity strategies, fixed income expertise, multi-asset solutions, systematic and quantitative approaches, and thematic global investments.

An agricultural technology platform specialising in fully automated indoor vertical farming systems. The platform designs and operates robotic farming environments that produce herbs and leafy greens using stacked growing systems within highly controlled conditions. The proprietary approach integrates robotics, in-house engineered equipment, and advanced lighting systems to optimise yield, quality, and nutritional outcomes, while significantly reducing water usage compared to conventional agriculture and eliminating the need for pesticides and herbicides. The model includes both owned-production operations and scalable deployment of large-format facilities, with a strategy focused on geographic expansion and localisation across key global markets.

A leading U.S. healthcare investment firm specialising in biopharmaceutical and medical technology opportunities across early clinical, late-stage, and commercial phases. The firm manages multiple investment strategies spanning private and public markets, with a focus on differentiated therapeutics, precision medicine, platform biotechnology, and medical devices supported by strong clinical evidence and clear regulatory pathways. The private investment strategy targets biopharma and medical technology companies with significant market potential and identifiable near-term clinical or regulatory inflection points, while the public-markets strategy provides exposure to a concentrated portfolio of high-conviction healthcare investments. The firm has an established history of co-investment activity, active portfolio value creation, and collaboration with clinical and research partners, and is supported by a broad institutional investor base across the U.S. and international markets.

A U.S.-based venture capital firm with a historical focus on early-stage life sciences, medical devices, biotechnology platforms, and healthcare technologies. The firm was founded and managed by an experienced partnership team and deployed multiple dedicated venture funds over several decades, backing high-growth companies across diagnostics, drug development, minimally invasive surgical technologies, implantable medical devices, and healthcare software. Investments were typically made at the Seed, Series A, and Series B stages, with the firm frequently acting as a lead or co-lead investor alongside established U.S. healthcare-focused venture funds. The portfolio has achieved a number of strategic exits through acquisitions by major global healthcare and medical technology companies.

A global private assets investment manager with approximately US$14 billion in assets under management, specialising in clean energy infrastructure, private equity secondaries, and U.S. middle-market private credit. The firm is among the largest independent renewable energy investors globally, with over 7 GW of renewable capacity developed across solar, wind, energy storage, and hybrid assets. Its clean energy strategies focus on the construction and operation of utility-scale renewable projects in OECD markets, targeting long-duration, contracted cash flows. In parallel, the private equity secondaries strategy targets mid-market transactions, including the acquisition of LP portfolios and complex GP-led restructurings, executed with a disciplined, risk-adjusted return approach. The U.S. middle-market credit strategy provides senior secured lending to high-quality borrowers, diversified across resilient, non-cyclical sectors. The firm has an established track record with institutional investors globally, including sovereign investors, pension funds, insurance companies, and ultra-high-net-worth clients.

A Boston-based, clinical-stage biotechnology company developing a first-in-class DNA-based immunotherapy targeting p62/SQSTM1, a protein overexpressed in multiple solid tumours. The therapeutic mechanism is designed to modulate the tumour microenvironment, reduce chronic inflammation, and enhance the effectiveness of existing cancer treatments, enabling combination use alongside chemotherapy, immunotherapy, or radiation therapy. Early-stage clinical results (Phase I/IIa) have been published in peer-reviewed oncology journals, demonstrating a favourable safety profile and encouraging signals of clinical activity, including disease stabilisation and restored sensitivity to chemotherapy in previously resistant patients. The company holds broad global intellectual property protection, including international patent filings and national registrations across the United States, Europe, and Asia. Phase II clinical trials are planned in the U.S. for indications including triple-negative breast cancer and ovarian cancer. The development strategy is oriented toward licensing or strategic acquisition following Phase II completion, with an anticipated multi-year pathway to a pharmaceutical partnership.

A deep-technology venture capital platform investing in transformative technologies across aerospace, defense, robotics, cybersecurity, biotechnology and longevity, semiconductors, advanced manufacturing, agri-technology, and next-generation energy systems. The platform is led by experienced entrepreneurs and investors and supported by a technical advisory network comprising former engineers, government research advisors, and leading scientists. It co-invests alongside top-tier venture funds in high-barrier, capital-intensive sectors where technological breakthroughs can generate asymmetric returns. The portfolio spans emerging category leaders across space, advanced mobility, satellite technologies, and industrial innovation. The strategy targets early-stage through growth-stage investments with a disciplined fund structure and a focus on companies operating at the intersection of science, defense, and industry.

A deep-technology venture-building platform focused on translating scientific research into high-growth companies addressing global challenges in human and planetary health. The platform collaborates with leading academic and research institutions to identify nature-inspired breakthroughs and transform them into commercially viable ventures. The model combines equity participation with significant volumes of non-dilutive research, innovation, and strategic funding support, enhancing capital efficiency and improving risk-adjusted outcomes across the portfolio. The platform is expanding its international footprint through collaboration with regional research ecosystems and industrial partners, aligning venture creation with national innovation agendas and long-term economic transformation priorities. Ongoing portfolio development is focused on sustainable chemistry, advanced materials, and computational life sciences.

This is a New York–based fundamental equity management company focused exclusively on emerging market and non-US technology opportunities. Founded in 2012 by an experienced investment professional with prior experience at leading global hedge funds, the company targets high-quality, category-leading businesses across technology, internet, financial technology, software, gaming, and digital infrastructure within emerging markets. The long-only strategy is managed as a concentrated portfolio of approximately 9–12 high-conviction positions, selected through deep fundamental research across a broad emerging-market technology universe. The company focuses on market leaders with strong competitive positioning, supported by structural tailwinds including digital adoption, demographic growth, and valuation differentials between emerging and developed markets.

An early-stage digital assets and blockchain investment platform providing exposure to high-growth crypto-native companies and token networks. The strategy focuses on ventures positioned to benefit from increasing institutional adoption, the development of blockchain-based financial infrastructure, and network-driven value creation. The platform operates a flexible "liquid venture" investment approach, deploying capital regularly across a curated set of early-stage opportunities using a mix of equity, token-linked, and token-based structures. Investment themes span decentralised finance, digital identity, blockchain infrastructure, tokenised assets, supply-chain solutions, Web3 developer tools, and peer-to-peer networks. The strategy typically co-invests alongside established global venture and digital-asset investors, offering diversified access to emerging blockchain ecosystems through professionally managed vehicles.

A potential acquisition opportunity involving a leading European provider of durable medical equipment, specialising in mobility and lifestyle solutions including powered mobility, assistive devices, long-term care equipment, and rehabilitation products. The business operates across multiple developed markets with a broad international footprint, supported by a large and established workforce. The company holds strong brand positions across several core product categories and serves a diversified customer base spanning healthcare providers, long-term care operators, and public-sector purchasers. The underlying market is supported by favourable structural tailwinds, including ageing populations, rising prevalence of chronic conditions, and increasing demand for home-based and assisted-living care solutions. The transaction presents an attractive entry point through a carve-out from a non-core parent, with multiple value-creation levers including margin improvement, supply-chain optimisation, product innovation, geographic expansion, and selective M&A consolidation.

A technology-focused investment platform managing multi-strategy global equity and venture capital mandates, structured across multiple thematic verticals spanning advanced technology, transformative innovation, and healthcare-related opportunities. The platform integrates early-stage, growth-stage, and public-markets strategies within a unified investment framework, supported by an experienced team of venture partners, advisors, and analysts. Backed by long-term anchor capital from a U.S.-based family office, the strategy is scaling toward a larger private capital platform.

A specialist life sciences investment platform focused on acquiring and optimising late-stage clinical and commercial-ready healthcare assets. The strategy partners with pharmaceutical, biotechnology, and academic institutions to identify undervalued or non-core therapeutics, applying rigorous scientific diligence, operational support, and structured capital solutions to accelerate value creation. Investments span areas such as oncology, rare diseases, immunology, and asset-backed healthcare portfolios, providing flexible capital structures that support continued development while preserving strategic optionality. The platform has an established track record of partnering with global biopharmaceutical groups to enhance commercialisation pathways and expand market access.

A UK-based digital diagnostics company developing a home-based Oral Glucose Tolerance Test (OGTT) for diabetes screening. The solution enables patients to complete the gold-standard test remotely, with results securely shared with clinicians, delivering clinical accuracy comparable to in-clinic testing while materially reducing cost and logistical burden. The company has raised institutional and angel capital to date and is progressing an interim funding round ahead of a planned Series A. Regulatory approvals have been secured across multiple jurisdictions, including the UK, Europe, and the Middle East, alongside inclusion on a national healthcare procurement framework. The solution is currently deployed across public healthcare providers and is expanding internationally across the Gulf, Asia-Pacific, and other selected markets. Supported by clinical validation from leading UK academic institutions, the technology addresses the global gestational diabetes screening market. The business is focused on scaling adoption across healthcare systems, with a pathway toward operating breakeven as commercial rollout accelerates.

The platform is a healthcare-focused private investment strategy backed by a diversified base of domestic and international institutional investors. The investment team brings deep sector expertise, with several decades of combined experience across private equity and healthcare, and has demonstrated strong performance across prior investment vehicles, with successful realizations and positive return trajectories. The current fund is a growth-stage healthcare vehicle targeting investments across the broader healthcare ecosystem, including healthcare delivery, diagnostics, pharmaceuticals, contract development and manufacturing, medical technology, and health-technology businesses. The strategy emphasizes proprietary sourcing, active governance, and value creation through operational support, strategic acquisitions, and responsible investment practices, including ESG and impact considerations. The fund typically targets minority positions, with average investment sizes aligned to growth capital needs, and seeks to deliver attractive risk-adjusted returns over the investment lifecycle.

A specialist alternative investment platform operates a digitised, asset-backed trade finance model facilitating international SME import and export transactions across global commodity markets. Rather than extending direct credit, the strategy acquires and controls underlying physical assets, transforming traditional counterparty credit risk into fully insurable, collateralised physical risk. Each transaction is supported by title transfer, marine all-risk insurance, and structural over-collateralisation mechanisms. Since inception, the platform has facilitated several thousand SME trade transactions across a broad range of commodities and jurisdictions, with a strong loss record and consistent net performance across multiple currency-denominated strategies. The funds are structured through established offshore fund domiciles and supported by institutional-grade service providers, including global administrators and auditors. A differentiated feature of the strategy is a dedicated net asset value protection framework, combining captive and third-party insurance arrangements designed to provide principal protection in downside scenarios and enhance capital preservation for investors.

A lower–mid-market private equity strategy focused on acquiring resilient, essential-services businesses across developed European markets. The approach targets companies with strong cash generation, stable demand profiles, and clear operational value-creation levers, including digitalisation, commercial optimisation, and buy-and-build execution. The strategy follows a long-established model of active ownership, sector specialisation, and hands-on operational improvement supported by an in-house value-creation capability. It builds on prior experience in defensive sectors such as healthcare services, education and training, financial administration, and technology-enabled services. Investments are typically made in established businesses with recurring revenues, diversified customer bases, and strong cash conversion, with a focus on compounding long-term value through disciplined underwriting, conservative leverage, and active portfolio management.

A cybersecurity services platform delivering managed security services, Security Operations Center (SOC) capabilities, compliance solutions, and cyber risk monitoring. The platform combines proprietary security technology with 24/7 managed detection and response, supporting enterprise, critical infrastructure, and public-sector clients. The strategic roadmap focuses on scaling SOC capabilities, integrating advanced threat intelligence, and enhancing the platform to provide continuous monitoring, rapid incident response, and compliance automation for mid-market and enterprise customers.

A specialised defence and robotics platform provides a mobile, containerised system designed for the safe destruction, thermal treatment, and processing of ammunition and military ordnance. The solution is modular in design, comprising multiple integrated units such as command and control, power generation, destruction, thermal treatment, and optional disassembly modules, and is engineered for deployment on mobile platforms for field operations. The technology is delivered together with licensed proprietary operating know-how and supported by technical and specialist services to enable safe and compliant operations. The overall structure includes long-term operational support, maintenance, and warranty coverage, with controlled deployment parameters aligned to regulatory and sovereign requirements.

A leading global private equity investor focused exclusively on the mining and metals sector, with more than two decades of investment experience and over US$4 billion committed across multiple flagship funds. The firm provides growth capital, operational enhancement support, restructuring expertise, and strategic financing to mining projects and mining-technology companies worldwide. The core private equity strategy targets late-stage development projects and producing assets with de-risked technical and operational profiles. A complementary credit strategy offers structured financing solutions to mining companies, including senior secured lending with potential equity participation, while an innovation-focused strategy supports early-stage mining technologies aimed at improving productivity, sustainability, and energy efficiency across the sector. The firm has executed multiple transactions in the Middle East, including structured investments with government-related entities in Saudi Arabia and the UAE, and is positioned as a specialist partner for institutional investors seeking diversified commodity exposure and access to critical and strategic minerals.

A Canadian clinical-stage biotechnology company focused on the development of broad-spectrum antiviral and anti-infective therapeutics. The core research approach centres on small-molecule formulations designed to inhibit viral replication across multiple pathogens, including influenza, coronaviruses, RSV, and other emerging respiratory viruses. The lead antiviral programme is positioned as a potential universal antiviral candidate, with preclinical data demonstrating activity across a wide range of viral families. In parallel, the company is advancing additional pipeline assets targeting anti-inflammatory and immune-modulatory treatments for respiratory conditions. The development strategy emphasises rapid and scalable formulation design, global regulatory pathways, and collaboration with clinical research partners to accelerate proof-of-concept validation. The approach addresses a growing global demand for pandemic-resilient antiviral solutions capable of responding to both seasonal infections and novel viral outbreaks.

An ASX-listed Australian mining and processing company focused on the production of neodymium–praseodymium (NdPr), a critical input for permanent magnets used in electric vehicles, wind turbines, and other clean-energy technologies. The company's flagship project in Australia's Northern Territory integrates a long-life open-pit mine with on-site processing facilities to produce separated NdPr oxides and other rare-earth products. Once fully ramped, the project is designed to supply approximately 4–5% of global magnet rare-earth demand, supported by a reserve life exceeding 30 years and government support in the form of loans, grants, and strategic backing from the Australian Commonwealth.

A Swedish–American energy technology company developing a next-generation thermochemical battery that integrates metal-hydride heat storage with a Stirling engine–based power conversion system. The technology has been co-developed in collaboration with a U.S. national laboratory under the Department of Energy framework and is exclusively licensed to the company, with performance and cost characteristics validated through independent analyses conducted by U.S. government and aerospace research institutions. The battery is designed for both grid-scale and distributed energy storage applications, offering long-duration storage without cyclic degradation, no reliance on rare-earth materials, and full recyclability. The solution is positioned as materially lower cost than conventional lithium-ion systems and competitive with fossil-fuel-based peaker plants. Headquartered in Northern Europe, the company operates research, development, and commercialization activities across the United States and Europe and is advancing toward commercial pilot deployments and large-scale manufacturing.

One of the largest and most active rental residential real estate developers in the United States, headquartered in the Southwest. Since its founding in 2000, the firm has developed or acquired more than 136,000 residential units across multifamily, workforce housing, senior living, and build-to-rent segments, representing over US$27 billion of capital invested. The portfolio spans multiple residential strategies, including luxury multifamily communities, attainable workforce housing, senior living developments, and build-to-rent residential neighbourhoods, alongside a complementary industrial real estate business focused on warehouse and distribution assets. The firm operates a nationwide platform across more than a dozen U.S. states and nearly 40 metropolitan markets, supported by a network of regional offices and a scaled operating infrastructure that combines local execution capabilities with centralized capital management and risk oversight.